Physician profile
Gene V Levinstein
NPI 1366494296
$6,812.15
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,765 · 2020: $528 · 2021: $90.50 · 2022: $85.99 · 2023: $137 · 2024: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $5,668.25 | 2019 | |
| Surgentec | $455.63 | 2020 | |
| Galderma Laboratories, L.P. | $339.88 | 2019-2024 | Dysport |
| Allergan, INC. | $121.53 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $38.54 | 2021 | |
| Biotronik Nro, INC. | $36.61 | 2023-2024 | Prospera, Biotronik |
| Collegium Pharmaceutical, INC. | $36.48 | 2019-2023 | Belbuca |
| Abbvie INC. | $21.58 | 2023 | |
| Pfizer INC. | $21.28 | 2021 | |
| Fidia Pharma USA INC. | $21.11 | 2023 | Hymovis |
| Biodelivery Sciences International, INC. | $19.23 | 2021 | |
| Merz Pharmaceuticals, LLC | $17.21 | 2024 | Xeomin |
| Nalu Medical, INC. | $14.82 | 2023 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Levinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.